Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line sunitinib before and after nephrectomy in metastatic clear cell renal cell carcinoma
2007-003054-28Phase 4Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Objective response rate at 12 weeks. Started Aug 2007; status: active.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2007-003054-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003054-28.